Europe Breast Cancer Screening Market Size and Forecast 2025–2033

The Europe Breast Cancer Screening Market is witnessing substantial expansion, driven by heightened awareness, technological innovation, and strong governmental backing. Valued at USD 1.12 billion in 2024, the market is projected to reach USD 2.43 billion by 2033, growing at a robust CAGR of 9.02% from 2025 to 2033.

Rising breast cancer incidence rates, advancements in imaging technologies, and Europe-wide screening initiatives are reinforcing the importance of early detection. Improved access to healthcare services and AI-powered diagnostic systems are further accelerating market growth across the region.

The report covers analysis by Application (Mammography Screening, MRI Screening, Ultrasound Screening), Population (Mammography Screening Population, MRI & Ultrasound Screening Population), along with Country and Company Analysis for 2025–2033.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=europe-breast-cancer-screening-market-mammography-mri-and-ultrasound-forecast-to-2022-1097-p.php

Europe Breast Cancer Screening Market Overview

Breast cancer screening refers to medical tests and imaging procedures designed to detect breast cancer before symptoms appear. Early detection significantly improves survival rates by enabling timely and targeted treatment.

The primary screening methods include:

·        Mammography

·        Ultrasound

·        Magnetic Resonance Imaging (MRI)

·        Genetic testing for high-risk individuals

Across Europe, breast cancer screening programs are strongly promoted through national healthcare systems. Many countries offer routine mammograms to women aged between 50 and 74 years, often free or subsidized. As awareness campaigns gain traction and healthcare infrastructure improves, participation rates continue to rise.

Technological advancements such as AI-assisted mammography, 3D tomosynthesis, and portable imaging devices are further strengthening early detection capabilities. With increasing accessibility and policy support, the demand for advanced screening technologies continues to grow.

Growth Drivers in the Europe Breast Cancer Screening Market

Government Initiatives and Awareness Programs

European governments play a central role in expanding screening coverage. Countries such as the United Kingdom, Germany, and France operate organized national screening programs offering routine mammography.

The European Union’s Beating Cancer Plan, part of the broader European Health Union strategy, aims to provide screening access to 90% of eligible populations. Such initiatives significantly boost participation rates and create demand for advanced diagnostic technologies.

Advancements in Screening Technologies

The adoption of digital mammography, AI-driven diagnostics, and 3D tomosynthesis is transforming breast cancer screening across Europe. AI-powered systems improve diagnostic accuracy by reducing false positives and false negatives, easing the workload on radiologists.

In March 2025, GE HealthCare introduced the Invenia™ Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound system enhanced with advanced AI capabilities designed to improve supplemental screening for patients with dense breast tissue.

Such innovations are accelerating modernization of diagnostic centers and hospitals across the region.

Rising Breast Cancer Incidence

Breast cancer remains the most common cancer among women in Europe. According to regional health statistics, the WHO Europe region recorded an estimated 604,900 new cases in 2022.

Aging populations, lifestyle changes, and genetic predispositions are contributing to increased risk, reinforcing the importance of structured screening programs.

Key Challenges in the Market

High Cost of Advanced Technologies

MRI and 3D mammography systems involve substantial capital investment. Not all healthcare facilities, particularly in lower-income regions, can afford these technologies. This cost barrier limits widespread adoption and creates disparities in screening access.

Accessibility Gaps

While Western European countries generally maintain high screening coverage, rural and underserved areas in parts of Eastern Europe still face infrastructure shortages. Mobile screening units and telemedicine initiatives are emerging solutions but have yet to fully eliminate regional inequalities.

Application Segment Analysis

Mammography Screening Market

Mammography remains the gold standard for breast cancer screening in Europe. Nationwide programs in several countries rely heavily on digital mammography and increasingly on 3D tomosynthesis for improved detection accuracy.

Government investments and systematic recall systems for eligible women continue to drive steady demand in this segment.

MRI Screening Market

Breast MRI is typically recommended for high-risk patients or those with dense breast tissue. Although MRI offers superior sensitivity in early tumor detection, high equipment and operational costs restrict its broader application.

MRI screening is more prevalent in advanced healthcare systems and private care networks.

Ultrasound Screening Market

Ultrasound is widely used as a supplementary tool alongside mammography, particularly for women with dense breast tissue. The integration of automated breast ultrasound systems (ABUS) is increasing screening precision and efficiency.

Hospitals and diagnostic centers are expanding ultrasound services to enhance early detection capabilities.

Population-Based Market Insights

The expansion of eligible screening populations is a key growth factor. Beyond the traditional 50–74 age bracket, some countries are extending coverage to younger high-risk women.

Genetic testing for BRCA1 and BRCA2 mutations is becoming more common, supporting personalized screening strategies and improving early intervention outcomes.

Country-Wise Market Analysis

Germany

Germany operates one of Europe’s most structured breast cancer screening programs, offering nationwide mammography for women aged 50–69 through statutory health insurance.

In February 2023, deep-tech startup Vara strengthened its AI screening capabilities by appointing a leading radiologist as medical advisor, reinforcing Germany’s leadership in AI-driven diagnostics.

France

France provides free mammography every two years for women aged 50–74. The French healthcare system actively promotes early detection and integrates digital imaging technologies.

In March 2024, Lunit expanded AI-powered radiology solutions in France, enhancing breast cancer detection accuracy.

United Kingdom

The UK’s screening efforts are led by the National Health Service (NHS).

National Health Service provides free mammograms to women aged 50–70 through its comprehensive Breast Screening Programme.

In February 2025, the UK government launched a major AI trial involving nearly 700,000 individuals across 30 screening sites in England to assess AI’s role in improving early detection rates.

Netherlands

The Netherlands maintains high participation rates through government-funded programs covering women aged 50–75. Mobile screening units improve rural access.

In October 2023, Agendia NV received approval for MammaPrint® inclusion in the national health insurance package, supporting personalized breast cancer care.

Competitive Landscape

Major pharmaceutical and healthcare companies contributing to the broader oncology and screening ecosystem include:

·        AstraZeneca

·        Novartis

·        Sanofi

·        Pfizer

·        Bayer AG

·        GlaxoSmithKline plc

These companies play a vital role in oncology therapeutics, research collaboration, and diagnostic innovation across Europe.

Market Segmentation Overview

By Application

·        Mammography Screening Market

·        MRI Screening Market

·        Ultrasound Screening Market

By Population

·        Mammography Screening Population

·        MRI & Ultrasound Screening Population

Country Coverage
United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, Netherlands.

Each company profile in the report is analyzed from five perspectives:

·        Overview

·        Key Persons

·        Recent Developments

·        Product Portfolio

·        Revenue

Final Thoughts

The Europe Breast Cancer Screening Market is entering a high-growth phase, driven by policy support, rising cancer prevalence, and rapid technological advancements. With market value expected to more than double from USD 1.12 billion in 2024 to USD 2.43 billion by 2033, screening services are becoming a cornerstone of preventive healthcare across the region.

Artificial intelligence, 3D imaging, and personalized screening strategies are redefining early detection standards. While challenges related to cost and accessibility remain, continued innovation and government commitment position Europe as a global leader in structured breast cancer screening.

As healthcare systems prioritize prevention over treatment, breast cancer screening will remain central to improving survival outcomes and enhancing women’s health across Europe.